Tocilizumab Prevents Progression of Early Systemic Sclerosis Associated Interstitial Lung Disease

ConclusionTocilizumab in early SSc ‐ associated interstitial lung disease with progressive skin disease stabilized forced vital capacity over 48 weeks, independent of the extent of quantitative radiographic interstitial lung disease or fibrosis.

Source: Arthritis and Rheumatology - February 4, 2021 Category: Rheumatology Authors: David Roofeh, Celia J F Lin, Jonathan Goldin, Grace Hyun Kim, Daniel E Furst, Christopher P Denton, Suiyuan Huang, Dinesh Khanna, The focuSSced investigators Tags: FULL LENGTH Source Type: research